TERT and neuroblastoma: The INFORM inclusion criteria might contribute to an underrepresentation of the most aggressive neuroblastomas, which are most likely MYCN-amplified or TERT-rearranged, since patients are required to have sufficient general condition and a life expectancy of at least three months to be included in the registry trial.